lifestyle.californiaconsumerbanking.com

Author: Alveus Therapeutics Inc

Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next‑Generation Therapies for Obesity and Metabolic Diseases

April 28, 2026
Alveus Therapeutics Announces FDA Clearance of IND and First Patient Dosed in Phase 1b Trial of ALV-100 for Obesity

January 23, 2026